India pharma faces tariff pressure from Trump

Indian pharmaceutical exports to the U.S. market face significant risks due to the U.S. administration's threat to impose high tariffs on alternative medicines imports. Washington has proposed imposing a 100% tariff starting in 2028, with the possibility of increasing it to 200% the following year, in an effort to promote domestic drug manufacturing and reduce reliance on imports. Indian industries are a key resilience factor in the global pharmaceutical market, accounting for about 37% of India's pharmaceutical exports to the United States, valued at nearly $26 billion in 2025. Despite substantial Indian investments in establishing factories and acquiring American companies, relocating the production of alternative medicines to the U.S. faces challenges related to operational costs and profit margins, which could ultimately lead to higher drug prices for American consumers. U.S. pressures may push Indian companies to focus on more profitable sectors such as biologics and specialized therapies. However, the tariff measures may remain susceptible to change before implementation, amid shifting political landscapes and upcoming presidential elections.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article